Nugen Medical Devices Inc · TSXV:NGMD
Nugen Medical Devices — Investor Presentation (February 2021)
20 slides from Nugen Medical Devices's investor presentation, February 2021
Slide 1: Revolutionizing Needle-Free Drug Delivery
NU MEDICAL DEVICES REVOLUTIONIZING Needle-Free DRUG DELIVERY
Slide 2: Our Vision
Introducing our new global branding as: Our Vision NuGen MD believes that every individual should have the opportunity to receive healthcare that is empowering, safe and respectful.
Slide 3: Disclaimer
DISCLAIMER 01 GENERAL The information provided in this presentation pertaining to NuGen Medical Devices ("NuGen MD" or "The Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any se
Slide 4: Global Market Opportunity
GLOBAL MARKET OPPORTUNITY Injections are a common healthcare procedure, administered to billions every day— but the technique is increasingly going needle-free. GLOBAL VACCINATION GLOBAL NEEDLE-FREE COVERAGE¹ INJECTION SYSTEM MARKET² Current and planned All market values in USD. $25.0B CAGR $10.1B (
Slide 5: Why Needle-Free? Benefits of Needle-Free
WHY NEEDLE-FREE? BENEFITS OF NEEDLE-FREE 03 Needle-free REDUCE COSTS delivery is much 05 Patients REDUCE FEAR report less pain and cheaper than the use of needles. discomfort with needle-free Cost Per Million Injections injections, making them more Source: GEN likely to adhere to medications. Conven
Slide 6: That's Where We Come In. How It Works
THAT’S WHERE WE COME IN. HOW IT WORKS High-pressure jet injections Traditional needle syringes The company dispense micro-droplets of penetrate the skin, causing medication evenly into the skin. medication to pool over time. has perfected its needle-free devices, NEEDLE-FREE NEEDLE which are now ava
Slide 7: From Concept to Commercialization
FROM CONCEPT TO COMMERCIALIZATION Platform development overview 2016 2019 2020 2005 Prototype of electric Jet-injectors ready for First prototypes of Re-design and powered Jet-injectors Commercialization spring powered mass production with automatic dosage and mass production Jet-injectors for optim
Slide 8: Global Reach
GLOBAL REACH GLOBAL OFFICES In progress: U.S., Canada, China EUROPE AMSTERDAM TORONTO ISRAEL FILING Q4 2020 SAUDI ARABIA TAIWAN The company has achieved SHENZHEN multiple regulatory approvals HONG KONG and is cleared to sell its devices in over 40 countries. MALAYSIA BRAZIL AUSTRALIA SOUTH AFRICA NE
Slide 9: Key Target Markets
KEY TARGET MARKETS NuGen Medical Devices can be applied across diverse markets for home healthcare such as diabetes and compatible with over 100 drugs and biologics. IVF Services Market Human Growth Hormone Market Global Diabetes Drug Market Adults with Diabetes CAGR (2019-2026): 9.3% CAGR (2020-202
Slide 10: Nanoparticle Powder Injectable
NANOPARTICLE POWDER INJECTABLE DISRUPTIVE NEXT-GENERATION DEVICE In emerging countries, camels deliver vaccines in refrigerated and solar-powered containers. THERMOSTABLE IMPROVED EFFICACY CONTROLLED RELEASE New powder drug Demonstrated possible Encapsulation offers the In contrast, nanoparticle-red
Slide 11: Nanojex - Powder Vaccine Injector
NANOJEX - POWDER VACCINE INJECTOR OWNED BY NUGEN MEDICAL DEVICES AND MANUFACTURED BY LOCAL CONTRACT MANUFACTURER. AN ENTIRELY CANADIAN SOLUTION. TRANSDERMAL, POWDER DRUG INJECTION TECHNOLOGY DEVELOPED BY: The patented “Nanojex System” painlessly delivers medicines through the skin, using a gas jet t
Slide 12: Timeline
TIMELINE Letter of intent Definitive Resulting issuer to acquire EPG agreement with branding maker of Insujet™ Capital Pool Company on the TSX Venture June BuzBuz Capital 2017 2020 October 2021 Q4 2019 September Closing of Engagement of Acquisition Cannacord Genuity Company of European Closing of $6
Slide 13: Notable Advisors
NOTABLE ADVISORS DR. CAMILLO RICORDI Director, Diabetes Research Institute VICENTE FOX DR. RONALD DENIS University of Miami Former President of Chief of Surgery Mexico Sacré-Coeur Hospital Montreal DR. RICHARD GALLO JOSEPH McCLENDON III Montreal Heart Author, Public Institute Speaker DR. CLAUDE VEZE
Slide 14: Board of Directors
BOARD OF DIRECTORS MICHAEL G. WRIGHT DEREK LINDSAY KAREN DUNLAP DR. JOHN LEOMBRUNO MICHAEL WEKERLE WILLIAM CLEMAN Chief Executive Proposed Director, Head Director Director Proposed Director Proposed Director Officer, President and of Audit Committee Director 13
Slide 15: Management Team
MANAGEMENT TEAM MICHAEL G. WRIGHT VERONIQUE LABERGE NICKY CANTON CHRIS BROWN MICHAEL LEBEUTF, JD Chief Executive Chief Financial Chief Operating Investor Relations, Corporate Secretary, Officer, President and Officer Officer Global Capital Markets Corporate Counsel Director 14
Slide 16: Why Invest? Poised to Perform
WHY INVEST? PROJECTED REVENUES In CAD Injectors $35M 120k $31.2M AGREEMENTS IN DEVELOPMENT 100K $30M injectors 100k In discussion with Specialty Pharma licensing deals POISED TO $25M 80k Direct-to-diabetic distribution strategy focused on clinics and hospitals PERFORM CUSTOMER PREDICTION Based on ma
Slide 17: Industry Competitors
INDUSTRY COMPETITORS Current Valuation Comparisons HO: Toronto, Canada Ivl Current Funding Round CADS4.0M a Previous R&D to commercialization CADS$18.0M Wh Valuation CAD$32M (pre-money) Wil nuGen MEDICAL DEVICES HQ: France Annual Revenue €2.1M/CAD$3.26M (H1' 2020) Total Funding Amount €100,000,000 M
Slide 18: Corporate Structure and Use of Proceeds
CORPORATE STRUCTURE AND USE OF PROCEEDS Uses of Proceeds * in Canadian dollars NuGen shares outstanding 63,789,702 Manufacturing Sales, Business General Product and Inventory Development Administration Development Options 628,333 $1,250,000 and Marketing $850,000 $500,000 $900,000 Warrants 7,925,159
Slide 19: Statutory Rights of Action for Damages or Rescission for Canadian Investors
STATUTORY RIGHTS OF ACTION FOR DAMAGES OR RESCISSION FOR CANADIAN INVESTORS Securities legislation in certain of the provinces of Canada provides purchasers with rights of rescission or damages, �or both, where an offering memorandum or any amendment to it contains a misrepresentation. A �“misrepres
Slide 20: NuGen Medical Devices are a catalyst to commercialization
NuGen Medical Devices are a catalyst to the commercialization of innovative needle-free solutions for the cure and care of the global community.
NuGen Medical Devices — Investor Presentation (February 2021) on 6ix